Decorum Pharmaceuticals Private Limited
Wholesale trading of pharmaceutical products since 2018, based in Patna, Bihar.
2018 | Patna, Bihar (India) | Active
Decorum Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 82.24%
- Profit Growth 192.48%
- Ebitda 194.34%
- Net Worth 8.20%
- Total Assets 1.88%
About Decorum Pharmaceuticals
Decorum Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 August 2018 (Six years and six months 7 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Naveen Dubey, Mitu Pandey, and Shambhoo Shrivastava serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999BR2018PTC038987
- Company No.
038987
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Pharma
Who are the key members and board of directors at Decorum Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Dubey  | Director | 30-Aug-2023 | Current |
| Mitu Pandey | Director | 23-Aug-2018 | Current |
| Shambhoo Shrivastava | Director | 23-Aug-2018 | Current |
Financial Performance of Decorum Pharmaceuticals.
Decorum Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 82.24% increase. The company also saw a substantial improvement in profitability, with a 192.48% increase in profit. The company's net worth moved up by a moderate rise of 8.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Decorum Pharmaceuticals?
In 2019, Decorum Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Decorum Pharmaceuticals?
Unlock and access historical data on people associated with Decorum Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Decorum Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Decorum Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.